John M Reno

This inventor holds 45 USPTO granted patents and 1 published patent application and 2 EPO patents, primarily in Targeted Therapeutics. Top assignees: Neorx Corporation, Aletheon Pharmaceuticals, Inc., Kaleidos Pharma, Inc.. Active years: 1989-2010.

USPTO Granted Patents = 45 (Patent Applications = 1)

% Patents Active = 82.2

EPO Patents = 2 (Patent Applications = 1)

Average Co-Inventor Count = 3.3

ph-index = 22

Forward Citations = 2,933(Granted Patents)

Location History:

Lynnwood, WA (US) (1989)
Brier, WA (US) (1990 - 2010)

Company Filing History:

Aletheon Pharmaceuticals, Inc.

patents

1 out of 3

Kaleidos Pharma, Inc.

Poniard Pharmaceuticals, Inc.

patents

6. 1 out of 1,831

Scimed Life Systems, Inc.

patents

7. 1 out of 7,680

The Dow Chemical Company

9. 2 out of 834,307

Other

patents

where one patent can have more than one assignee

Years Active: 1989-2010

Loading Chart...

Areas of Expertise:

Targeted Therapy

Pretargeting Methods

Radiolabeled Agents

Vascular Smooth Muscle Inhibitors

Humanized Antibodies

Small Molecular Weight Ligands

Biotin Conjugates

Hepatic-Directed Compounds

Diagnostic Proteins

Antibody Fragments

Clearing Agents

Trichothecene Conjugates

45 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 7744853 - Radiolabeled annexins (2010-06-29),

2. 7144991 - Streptavidin expressed gene fusions and methods of use thereof (2006-12-05),

3. 7115248 - Radiolabeled annexins (2006-10-03),

4. 7078013 - Pretargeting methods and compounds (2006-07-18),

5. 6720350 - Therapeutic inhibitor of vascular smooth muscle cells (2004-04-13),

6. 6709652 - Pretargeting methods and compounds (2004-03-23),

7. 6677307 - TGF-&agr; polypeptides, functional fragments and methods of use therefor (2004-01-13),

8. 6663881 - Therapeutic inhibitor of vascular smooth muscle cells (2003-12-16),

9. 6569441 - Therapeutic inhibitor of vascular smooth muscle cells (2003-05-27),

10. 6491938 - Therapeutic inhibitor of vascular smooth muscle cells (2002-12-10),

11. 6416738 - Pretargeting methods and compounds (2002-07-09),

12. 6358989 - Therapeutic inhibitor of vascular smooth muscle cells (2002-03-19),

13. 6358710 - Humanized antibodies that bind to the antigen bound by antibody NR-LU-13 (2002-03-19),

14. 6358490 - Three-step pretargeting methods and compounds (2002-03-19),

15. 6306421 - Therapeutic inhibitor of vascular smooth muscle cells (2001-10-23),

Title: Unveiling the Innovations of John M Reno

Introduction:

Meet John M Reno, a prolific inventor based in Brier, WA, US, with an impressive track record of 45 patents under his belt.

Latest Patents:

1. Radiolabeled annexins: John M Reno's innovation focuses on radiolabeled annexins and modified annexin conjugates used for imaging vascular thrombi. The methods for creating and utilizing these radiolabeled annexin conjugates are also elucidated.

2. Streptavidin expressed gene fusions: His recent invention delves into vectors designed for expressing genomic streptavidin fusion cassettes. These vectors produce fusion proteins, including a single-chain antibody and genomic streptavidin, with various applications such as diagnostic markers and cell-specific targeting agents.

Career Highlights:

John M Reno has contributed his inventive prowess to renowned companies such as Neorx Corporation and Aletheon Pharmaceuticals, Inc.

Collaborations:

During his tenure, John M Reno collaborated with notable individuals like Louis J Theodore and Linda M Gustavson, fostering a culture of innovation and excellence.

Conclusion:

In conclusion, John M Reno stands as a testament to ingenuity and creativity in the realm of inventions. His groundbreaking work in radiolabeled annexins and streptavidin expressed gene fusions reflects his dedication to pushing the boundaries of scientific discovery.